Targeting IL-33 in chronic obstructive pulmonary disease (COPD), chronic asthma and idiopathic pulmonary fibrosis (IPF)

靶向 IL-33 治疗慢性阻塞性肺疾病 (COPD)、慢性哮喘和特发性肺纤维化 (IPF)

• 批准号: nhmrc : 1120152
• 金额: $ 21.75万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-il-33-fibrosis-ipf/946444
• 关键词: Targeting; IL; 33; chronic; obstructive

Lung diseases (emphysema, severe asthma & pulmonary fibrosis) are major burdens on Australian community and economy. Airway wounding is a key feature of all these diseases. Patients experience severe breathlessness seriously impacting quality of life and frequently leading to death. We will assess the potential of a new target (IL-33), & therapy (anti-IL-33) in suppressing wounding in experimental models and human tissues. This may lead to a new treatment to reverse and/or prevent lung diseases.

肺病(肺气肿、严重哮喘和肺纤维化)是澳大利亚社区和经济的主要负担。呼吸道损伤是所有这些疾病的一个关键特征。患者出现严重的呼吸困难，严重影响生活质量，并经常导致死亡。我们将评估一种新的靶点(IL-33)和疗法(抗IL-33)在抑制实验模型和人体组织创伤方面的潜力。这可能导致一种新的治疗方法来逆转和/或预防肺部疾病。